Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
about
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyNilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
P2860
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Beyond dose escalation: clinic ...... chronic myelogenous leukemia.
@en
Beyond dose escalation: clinic ...... chronic myelogenous leukemia.
@nl
type
label
Beyond dose escalation: clinic ...... chronic myelogenous leukemia.
@en
Beyond dose escalation: clinic ...... chronic myelogenous leukemia.
@nl
prefLabel
Beyond dose escalation: clinic ...... chronic myelogenous leukemia.
@en
Beyond dose escalation: clinic ...... chronic myelogenous leukemia.
@nl
P1476
Beyond dose escalation: clinic ...... n chronic myelogenous leukemia
@en
P2093
Hagop Kantarjian
Jorge Cortes
P304
P478
P577
2008-03-01T00:00:00Z